Long-term improvement in functional dyspepsia using hypnotherapy

Calvert, Emma; Houghton, Lesley A.; Cooper, Patricia; Morris, Julie; Whorwell, Peter J.

doi:10.1053/gast.2002.37071

Cited by 228 publications

(185 citation statements)

References 26 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Psychotherapy. In contrast to IBS, psychotherapy has rarely been tested in functional dyspepsia and has not been shown to be effective: only four controlled trials [210][211][212][213] were published until 2002 and an updated 2011 Cochrane analysis was withdrawn for unknown reasons. Three additional trials [214][215][216] were performed since the first Cochrane review, and all seven trials together covered the entire spectrum of psychotherapy options, but each technique was tested only in a single, small study (TABLE 2).…”

Section: Pharmacological Treatment Of Epsmentioning

confidence: 99%

“…Two arms, control (supportive therapy) and treatment (7 sessions: the first 3 hours long, then 6 × 50-minute sessions) over 4 months (73; 19%) • At the end of treatment: significantly better total symptom scores in both gastroenterologist's and patient's reports in the treatment arm compared with controls • At 1-year follow-up: similar symptomatic scores Hypnotherapy (Calvert et al 213 ) Three arms, two control conditions (supportive therapy plus placebo medication or medical treatment alone) and treatment (12 × 30-minute sessions) over 4 months (126; 16%)…”

Section: Quality Of Lifementioning

confidence: 99%

See 1 more Smart Citation

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

260

247

View full text Add to dashboard Cite

| Functional dyspepsia is one of the most prevalent functional gastrointestinal disorders. Functional dyspepsia comprises three subtypes with presumed different pathophysiology and aetiology: postprandial distress syndrome (PDS), epigastric pain syndrome (EPS) and a subtype with overlapping PDS and EPS features. Functional dyspepsia symptoms can be caused by disturbed gastric motility (for example, inadequate fundic accommodation or delayed gastric emptying), gastric sensation (for example, sensations associated with hypersensitivity to gas and bloating) or gastric and duodenal inflammation. A genetic predisposition is probable but less evident than in other functional gastrointestinal disorders, such as irritable bowel syndrome (IBS). Psychiatric comorbidity and psychopathological state and trait characteristics could also play a part, although they are not specific to functional dyspepsia and are less pronounced than in IBS. Possible differential diagnoses include Helicobacter pylori infection and peptic ulceration. Pharmacological therapy is mostly based on the subtype of functional dyspepsia, such as prokinetic and fundus-relaxing drugs for PDS and acid-suppressive drugs for EPS, whereas centrally active neuromodulators and herbal drugs play a minor part. Psychotherapy is effective only in a small subset of patients, whereas quality of life can be severely affected in nearly all patients. Future therapies might include novel compounds that attempt to treat the underlying gastric and duodenal inflammation. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17081 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .standard therapy for gastro -oesophageal reflux disease. Paediatric dyspeptic symptoms are being addressed in a separate classification effort 10 . This Primer covers functional dyspepsia in adults only, although we sporadically refer to paediatric functional dyspepsia when similarities exist. EpidemiologyThe population prevalence of functional dyspepsia is quite variable across the globe, with overall high numbers (10-40%) in Western countries and low numbers (5-30%) in Asia, independent of the respective functional dyspepsia definitions 11 . A large-scale health and nutrition survey from France 12 (which involved >35,000 people) identified that 15% of individuals had suspected functional dyspepsia, 28% had irritable bowel syndrome (IBS) and 6% had both. The population of patients who are affected by both IBS and functional dyspepsia has been reported to range between 10% and 27% in previous studies 13 and to approach 30% in popu lation samples; it could be even higher in specific populations 14,15 . This observation has given rise to the term 'overlap syndrome' (REF. 13), which calls into question the sensitivity and specificity of the Rome criteria, at least for IBS and functional dyspepsia. This argument is also supported by the observation that patients with functional dyspepsia m...

show abstract

Section: Pharmacological Treatment Of Epsmentioning

confidence: 99%

Section: Quality Of Lifementioning

confidence: 99%

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

260

247

View full text Add to dashboard Cite

show abstract

“…However, no efficacy has been proven, either for the drugs described above or for autogenic training for autonomic nervous system intervention. Few studies confirm the effectiveness of hypnotherapy, although their results suggest that hypnotherapy may be more effective than drug therapy for the treatment of FD [71]. One study showed the efficacy of transcutaneous electroacupuncture in the treatment of FD [72], but in another study the results of classical six-point manual acupuncture could not be differentiated from the placebo [73].…”

Section: Treatmentmentioning

confidence: 99%

Evidence-based clinical practice guidelines for functional dyspepsia

et al. 2015

View full text Add to dashboard Cite

General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world's first country to list ''functional dyspepsia'' as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor-patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.

show abstract

“…Hypnosis is a well known relaxation and stress management technique that has been used by gastroenterologists to treat irritable bowel syndrome and to decrease peptic ulcer relapse. 16,17 Hyperemesis gravidarum 18 and functional dyspepsia 19 can also be improved by hypnotherapy. 18 However, hyperemesis gravidarum is commonly believed to be psychogenic in origin with no impairment of gastric function.…”

Section: Introductionmentioning

confidence: 99%